117 related articles for article (PubMed ID: 2685857)
1. [Neurochemical perspectives of the function of monoamine oxidases].
Riederer P; Konradi C; Hebenstreit G
Psychiatr Prax; 1989 Aug; 16 Suppl 1():7-10. PubMed ID: 2685857
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical perspectives to the function of monoamine oxidase.
Riederer P; Konradi C; Hebenstreit G; Youdim MB
Acta Neurol Scand Suppl; 1989; 126():41-5. PubMed ID: 2618592
[TBL] [Abstract][Full Text] [Related]
3. [Inhibitory monoamine oxidases of the new generation].
Nowakowska E; Chodera A
Pol Merkur Lekarski; 1997 Jul; 3(13):1-4. PubMed ID: 9432289
[TBL] [Abstract][Full Text] [Related]
4. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.
Riederer P; Konradi C; Schay V; Kienzl E; Birkmayer G; Danielczyk W; Sofic E; Youdim MB
Adv Neurol; 1987; 45():111-8. PubMed ID: 3030067
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Youdim MB; Bakhle YS
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S287-96. PubMed ID: 16402116
[TBL] [Abstract][Full Text] [Related]
6. The role of MAO in dopaminergic transmission.
Riederer P; Konradi C; Youdim MB
Adv Neurol; 1990; 53():149-53. PubMed ID: 2173368
[No Abstract] [Full Text] [Related]
7. Progress in monoamine oxidase (MAO) research in relation to genetic engineering.
Nagatsu T
Neurotoxicology; 2004 Jan; 25(1-2):11-20. PubMed ID: 14697876
[TBL] [Abstract][Full Text] [Related]
8. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons.
Demarest KT; Smith DJ; Azzaro AJ
J Pharmacol Exp Ther; 1980 Nov; 215(2):461-8. PubMed ID: 7441510
[TBL] [Abstract][Full Text] [Related]
9. The role of MAO in MPTP toxicity--a review.
Glover V; Gibb C; Sandler M
J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762
[TBL] [Abstract][Full Text] [Related]
10. On the role of monoamine oxidase-A for the maintenance of the volitional consumption of ethanol in two different rat models.
Mega BT; Sheppard KW; Williams HL; McMillen BA
Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):319-26. PubMed ID: 12237745
[TBL] [Abstract][Full Text] [Related]
11. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?
Damier P; Kastner A; Agid Y; Hirsch EC
Neurology; 1996 May; 46(5):1262-9. PubMed ID: 8628464
[TBL] [Abstract][Full Text] [Related]
12. Increase of monoamine oxidase-B activity in the brain of scrapie-infected hamsters.
Adjou KT; Dilda P; Aumond P; Gueddari S; Deslys JP; Dormont D; Seman M
Neurochem Int; 2008 Jun; 52(8):1416-21. PubMed ID: 18442871
[TBL] [Abstract][Full Text] [Related]
13. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.
Cohen G
Adv Neurol; 1987; 45():119-25. PubMed ID: 3030068
[No Abstract] [Full Text] [Related]
14. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
15. Cellular expression of mRNAs encoding monoamine oxidases A and B in the rat central nervous system.
Luque JM; Kwan SW; Abell CW; Da Prada M; Richards JG
J Comp Neurol; 1995 Dec; 363(4):665-680. PubMed ID: 8847423
[TBL] [Abstract][Full Text] [Related]
16. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
Cohen G
J Neural Transm Suppl; 1983; 19():89-103. PubMed ID: 6321651
[TBL] [Abstract][Full Text] [Related]
17. Hydrogen peroxide enhances the activity of monoamine oxidase type-B but not of type-A: a pilot study.
Konradi C; Riederer P; Youdim MB
J Neural Transm Suppl; 1986; 22():61-73. PubMed ID: 3097261
[TBL] [Abstract][Full Text] [Related]
18. The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission.
Napolitano A; Cesura AM; Da Prada M
J Neural Transm Suppl; 1995; 45():35-45. PubMed ID: 8748607
[TBL] [Abstract][Full Text] [Related]
19. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
Palfreyman MG; McDonald IA; Zreika M; Cremer G; Haegele KD; Bey P
J Neural Transm Suppl; 1993; 40():101-11. PubMed ID: 8294896
[TBL] [Abstract][Full Text] [Related]
20. Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes.
Lenders JW; Eisenhofer G; Abeling NG; Berger W; Murphy DL; Konings CH; Wagemakers LM; Kopin IJ; Karoum F; van Gennip AH; Brunner HG
J Clin Invest; 1996 Feb; 97(4):1010-9. PubMed ID: 8613523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
